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Purpose: This paper focuses on the characterization of polymeric micelle-forming tuberculostatic 
prodrugs and the antimycobacterial activity of these prodrugs. 
Method: By the condensation of hydroxymethylpyrazinamide, isoniazid and rifampin with free carboxyl 
groups on the copolymer poly(ethyleneglycol)-poly(aspartic acid), micelle-forming carrier-drug 
conjugates were obtained. These micelles were characterized by dynamic light scattering, to measure 
the micelle diameter;  by acid-base titration, to determine the percentage of carboxylic groups occupied 
by the tuberculostatic; by Sudan III solubility tests, to estimate the critical micelle concentration (CMC);  
and visual control and spectrophotometric measurement, to determine the stability of micelles. These 
micelles were tested in vitro against several Mycobacterium  strains. 
Results: As expected, the size and distribution of the micelle-forming tuberculostatic prodrugs found to 
be small (78.2nm, 84.2nm and 98.9 nm) while the level of the drug conjugated was high (65.02-85.7%). 
Furthermore, the micelles were stable in vitro, exhibiting a low level of CMC and stronger anti-
mycobacterial activity than the original drugs. 
Conclusion: The results demonstrate that polymeric micelles can be used as efficient carriers for drugs, 
which alone, exhibit undesired pharmacokinetics, poor solubility, and low stability. The synthesized 
micelle-forming tuberculostatic prodrugs opens a perspective of alternative prodrugs that prolong action 
and decrease the toxicity of the tuberculostatic drugs of choice. 
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INTRODUCTION 
Despite the great amount of scientific data 
amassed on tuberculosis (TB), an infection that 
has afflicted the human race for thousands of 
years, there is still no victory in sight over the 
disease, which today represents a severe 
problem for public health in many parts of the 
world, especially in the poorer countries. With 
the constantly growing number of multidrug 
resistant strains and the spread of AIDS, which 
destroys patients` immunity, leaving them much 
more susceptible to mycobacterial infection, the 
rates of incidence and prevalence of TB have 
been rising and could threaten the 
socioeconomic development of affected 
countries, in view of the fact that both TB and 
AIDS affect, in the main, people in their most 
productive years, aged 15-49
1,2
. 
While it is true that very useful tuberculostatic 
products exist, both for treatment and 
prophylaxis, the known toxic side-effects of 
these drugs, the infection of patients by the M. 
avium complex and their lack of adherence to 
the course of treatment, are all factors that make 
the ongoing search for improved drugs 
absolutely indispensable. As a rule, new drugs 
are introduced by modifying molecules with 




routes that are designed to begin with a known 
drug and make planned improvements in some 
of its properties, particularly in its 
pharmacokinetics (as is the case in delayed-
action prodrugs) are often used
3,4,5
. Prodrugs are 
chemicals with little or no pharmacological 
activity, undergoing biotransformation to a 
therapeutically active metabolite. In the prodrug 
approach, the physicochemical properties of the 
parent drug are transiently modified with a 
promoiety or carrier
4
. The objectives of a 
prodrug strategy are: to solve problems resulting 
from poor solubility, insufficient chemical stability 
or poor organoleptic properties; reduced 
systemic toxicity; improved oral bioavailability, by 
improving the oral absorption of the drug and/or 
by decreasing its presystemic metabolism. Other 
objectives are to improve absorption, lengthen 
the duration of action of the drug by slow 
metabolic release, and finally achieve the 





Even though great advances have been made in 
polymeric drugs, the practice of conjugating 
hydrophobic drug moieties in dense clusters 
along the polymer chain of a carrier molecule 
and, not infrequently, the low water solubility of 
the carrier itself, can easily result in the 
precipitation of the polymer derivative, and often 
does 
5, 6, 7, 8
.  To overcome this problem, a 
promising technique is to make polymer drugs 
that take the form of micelles
 5, 6, 7, 8
. In line with 
this approach, micelle-forming polymer 
derivatives of the initial-phase anti-tuberculous 
drugs - pyrazinamide, isoniazid and rifampin - 
were synthesized in this study. These derivatives 
were characterized by determining the critical 
micelle concentration (CMC) and the mean 
diameter of the micelles, and then tested for 
activity against several mycobacterial strains, 
such as virulent M. tuberculosis and M. avium.  
 
Materials and methods 
Chemicals  
Pyrazinamide (PZA), isoniazid (INH) and 
rifampin (RMP) were obtained from FURP 
(Popular Remedy Foundation), α-methyl-ω-
aminopoly(oxyethylene) (CH3–PEG–NH2, MW 
5,000) was purchased from Shearwater, Inc., 
USA, and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) from Aldrich. Other reagents 
were obtained from a variety of commercial 
sources. 
Synthesis 
The synthetic pathways of the micelle-forming 
polymer derivatives of PZA, INH and RMP are 
shown in Scheme 1. The synthetic procedures 
used have been published in detail elsewhere
 
9,10
. The products isolated at each step were 
lyophilized. β-Benzyl-L-aspartate [BLA]11 
compound (3), was produced by allowing 
aspartic acid and benzyl alcohol to react in 
sulfuric acid for 24h, with magnetic stirring, at 
13-17°C, and isolated by adding pyridine and 
chilling at -30°C overnight, to precipitate the 
product, which was recrystallized from water by 
adding pyridine dropwise. Phosgene gas was 
bubbled through a suspension of BLA in dioxan, 
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, to obtain a solution of compound 
(5), β-benzyl-L-aspartate N-carboxyanhydride 
(NCA-BLA). Solvent and excess phosgene were 
removed and the product mixed with 1:1 
petroleum ether / ethyl acetate; the resulting 
precipitate, after being filtered, was taken up in 
1:1 chloroform/butanol mixture and chilled at -
30°C to isolate solid NCA-BLA. The latter was 
allowed to react with CH3-PEG-NH2 for 24h in a 
stirred solution, under flowing argon, and then 




, which was 
precipitated in 1:1 ethanol/water, redissolved in 
chloroform and reprecipitated in 2-propanol at 
40°C. Next, alkaline hydrolysis of this copolymer 
at 0°C, carried out with 0.43M NaOH dissolved 
in 1:2:2 water/propanol/methanol, led to 
compound (8), poly(ethylene glycol)-
poly(aspartic acid) (PEG-PASP)
5,6
. After 10min 
of stirring, the alkali was neutralized with acetic 
acid and the mixture poured into ethyl ether. The 
precipitate was filtered, dissolved in water and 




 was produced by mixing 
pyrazinamide, 4% (w/v) potassium carbonate 
solution and 40% (v/v) formaldehyde, stirring for 
20h at room temperature and finally adding an 
equal volume of 40% formaldehyde. After total 
removal of the solvent, the solid residue was 
recrystallized from a solution in water/acetone 
(10:90). Three end-products were formed by 
conjugating the tuberculostatic compounds to 
the PEG-PASP polymer chain, as follows: 
isoniazid (INH, 14),  rifampin (RMP, 16) or 
hydroxymethylpyrazinamide (PZACH2OH, 11) 
was dissolved in N,N–dimethylformamide, (DMF) 
and the solution added to the aqueous solution 
of PEG-PASP together with the condensing 
agent, EDC (12). After 4h stirring at 0°C, more 
EDC was added and the reaction mixture stirred 
at room temperature for 24h. The resulting 
solution was dialyzed against 0.1M acetate 
buffer (pH 4.5) in a membrane with a 1000-
dalton cut-off for 4h, then against distilled water 
for an equal time and finally lyophilized to a 
semi-solid. The conjugated polymers thus 
obtained were PEG-PASP-PZA (13), PEG-
PASP-INH (15) and PEG-PASP-INH-RMP (17).  
Bacterial Strains 
The following strains of Mycobacterium were 
used to assay the polymer prodrug derivatives: 
M. tuberculosis standards H37Ra (American 
Type Culture Collection – ATCC 25177) and 
H37Rv (ATCC 27294), denoted Ra and Rv 
respectively; M. avium (denoted Ma – ATCC 
25291), M. kansasii (Mk – ATCC 12478), M. 
intracellulare (Mi – ATCC 13950) and M. 
malmoense (Mm – ATCC 29571).  
 
Determination of Minimum Inhibitory 
Concentration (MIC)
14
 – in vitro assay 
All the wells around the edge of a 96-well 
microplate were filled with 200µL sterile distilled 
water. Next, the wells B to G of columns 3 to 9, 
10 and 11 received, respectively, 100, 150 and 
200 µL of mycobacterial liquid growth medium, 
7H9. Stock solutions of 8.9 mg/mL of the three 








the prodrug carrier (PEG-PASP) were used to 
prepare dilutions of 3,560 or 356 µg/mL, 50 and 
100 µL of which were pipetted into wells B to G 
of columns 2 and 3, respectively. After thorough 
mixing, 100 µL of mixture was transferred from 
each well (B to G) in column 3 to the 
corresponding well in column 4, then from 
column 4 to 5 and so on, until the final dilution in 
column 9, from which 100 µL was discarded, 
after mixing. Lastly, 100 µL of a suspension of 
mycobacteria was added to every well from B to 
G in all columns except 2 and 11. This inoculum 
was taken from a culture grown for 10 days in 
7H9 medium at 37°C whose turbidity was 
adjusted to the McFarland No.1 scale and which 
was then diluted 25 times.  
Thus, in the M. tuberculosis microplates, the 
diluted drug stock was 356 µg/mL and every well 
in columns 3 to 9 contained a final volume of 200 
µL, with drug dilutions between 89.0 and 5.56 
µg/mL and an inoculum of Ra or Rv bacteria. For 
the Ma, Mk, Mi and Mm assays, microplates 
were prepared with the 3560 µg/mL drug stocks, 
giving dilutions (in columns 3 to 9) of 890 to 55.6 
µg/mL. The microplates were sealed with 
parafilm and incubated at 37°C for 5 days, after 
which 25 µL of a freshly-prepared solution of the 
redox dye Alamar Blue (1:1 v/v) in 10% Tween  
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Scheme 1. Synthetic pathway for micelle-forming polymer derivatives of isoniazid, pyrazinamide and rifampin. 
 80 solution was added to well B10, which was 
resealed and the plate returned to the incubator 
for another 24h. Assuming the medium in well 
B10 turned pink (indicating cell growth), the 
Alamar Blue solution was added to all wells and 
the plate incubated at 37°C for another 24h, at 
the end of which the color of each well was 
recorded. The tuberculostatic MIC was taken as 
the lowest concentration of the drug that 
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prevented the medium changing from blue to 
pink, i.e., which halted growth of mycobacteria.  
 
Determination of Critical Micelle 
Concentration (CMC) 
Aqueous solutions of PEG-PASP-PZA, PEG-
PASP-INH and PEG-PASP-INH-RMP were 





 mg/L, and 10mg of the stain Sudan 
III was added to 10mL to each solution. The 
absorbance of light by the solution at 519nm was 
measured with a Shimadzu UV1601 PC 
spectrophotometer over a 1cm light-path, to 
evaluate the apparent solubility of the stain in the 
micelle suspension. Each experiment was 
performed in triplicate. 
 
Estimation of Diameter of Micelles 
Solutions of 1% (w/v) PEG-PASP-PZA, PEG-
PASP-INH and PEG-PASP-INH-RMP in water 
were passed through Amicon YM3 43mm PK 
ultrafiltration membranes. The diameters of the 
micelles in the filtered polymer solutions were 
then estimated by measuring their dynamic light 
scattering in a Malvern 4,700 MW system, 
equipped with a 60mW He/Ne laser operating at 
632.8 nm (Spectra-Physics 107) and a 
thermostatic bath. Each experiment was 
performed in triplicate. 
 
Determination of free carboxyl groups 
The proportions of free carboxyl groups in the 
derivatives PEG-PASP-PZA, PEG-PASP-INH 
and PEG-PASP-INH-RMP were found by 
titrating these polymers and the original 
copolymer PEG-PASP, in aqueous solution, 
against 0.01M NaOH using phenolphthalein as 
indicator. Each experiment was performed in 
triplicate. Release of tuberculostatic drugs  from the 
micelles Dialysis bags (cut-off 1000) each 
containing the INH, RMP and PZA-loaded 
micelle suspension with 300–400 mg/ml of INH, 
RMP and PZA were placed in a dialysate with 
ten times excess volume at 37 
o
C. Phosphate 
buffered saline (PBS; pH 7.4) or 0.1 M acetate 
buffer (pH 5.0) was used as the micelle medium 
and dialysate. At a certain time interval, the 
micelles solutions in the dialysis bag were 
sampled and subjected to photometric assay at 
485 nm to determine the residual INH, RMP and 





For this purpose, lyophilized and aqueous 
solution of polymeric micelles were placed in a 
climatic chamber at 25 ± 2 
o
C, 60% relative 
humidity for 3 months. Lyophilized forms were 
placed in 2 ml Eppendorf tubes and solution 
forms were placed in 5 ml colored bottle with a 
lid. Samples were taken to determine the drug 
content at the beginning and at the end of 3 
months. Drug content was measured 
spectrophotometrically after extracting drug into 




Derivatives of the copolymer PEG-PASP, 
containing moieties of the drugs pyrazinamide, 
isoniazid and rifampin, were successfully 
synthesized by condensation with free carboxyl 
groups on the PASP segments of the carrier. 
The drug substituents were satisfactorily 
detected in the purified polymer derivatives by 
spectrometric analysis and the non-polymer 
intermediates involved in the synthetic pathway 
were identified by elemental analysis, 
spectrometric analysis and spectrophotometry. 
Taking the titrated free carboxyl groups in PEG-
PASP as 100%, the proportion substituted by 
isoniazid was 65.02% (≡4.03x10
-4
 mol INH per 
gram PEG-PASP-INH). It follows that the fraction 
of free carboxyl groups in the INH derivative was 
2.01x10
-4
 mol COOH/g. Out of these free 
groups, 52.5% were substituted by rifampin, 
giving a total of 1.05x10
-4
 mol RMP per gram 
PEG-PASP-INH-RMP. Thus, the fraction of free 
carboxyl groups in PEG-PASP substituted by 
INH and RMP in the two-drug derivative was 
82.04%. In the pyrazinamide derivative, 85.7% 
(4.9706x10
-4 
mol/g) of the free carboxyls were 
substituted by PZA.  
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Fig 1:  Determination of CMC of PEG-PASP-PZA (curve 1), PEG-PASP-INH (curve 2) and PEG-PASP-INH-RMP (curve 3). 
 
 
Fig 2: Determination of micelle diameter of PEG-PASP-PZA (curve 1), PEG-PASP-INH (curve 2)  
and PEG-PASP-INH-RMP (curve 3). 
 





 INH (15) RMP (17) PZA (13) (PEG-PASP) 
Ra ≤0.031 ≤0.031 ≤0.125 ≤5.56 ≤6.25 ≤6.25 I 
Rv ≤0.031 ≤0.031 ≤0.125 ≤5.56 12.5 12.5 I 
Ma >128.0 >128.0 ≤8.0 111.2 162 162 I 
Mk >128.0 >128.0 ≤8.0 ≤55.6 162 162 I 
Mi >128.0 >128.0 ≤8.0 ≤55.6 162 162 I 
Mm 128.0 >128.0 ≤8.0 445.0 162 162 I 
PEG-PASP – in vitro is devoid of pharmacological activity; (I: INATIVE) 
(15): PEG-PASP-INH;   (13): PEG-PASP-PZA;   (17): PEG-PASP-INH-RMP 
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Critical Micelle Concentration 
To verify and characterize the formation of 
micelles, the CMC was determined by plotting 
the solubility of Sudan III stain (at an absorbance 
of 519 nm) in aqueous solutions of the polymer 
derivatives against polymer concentration and 
observing the threshold above which micelles 
form, providing a phase in which the stain is 
soluble. The CMC of PEG-PASP-PZA and PEG-
PASP-INH was 5.0 x 10
-4
 mg/L and that of PEG-
PASP-INH-RMP, 5.0 x 10
-5
 mg/L, as can be 
verified from Figure 1.  
 
Micelle Diameter 
The dynamic light-scattering results displayed in 
Figure 2 shows that the mean diameters of the 
micelles were: 78.2nm for PEG-PASP-PZA, 




The antibacterial MIC results (in a pH7 medium) 
are expressed in terms of the total weight of 
each derivative or drug standard. INH, RMP, 
PZA and their derivatives were tested against 
the mycobacterial strains (Ra, Rv, Ma, Mk, Mi 
and Mm). In a preliminary assay, PZACH2OH 
was tested against Ra and exhibited 
tuberculostatic activity (MIC of 24.8 µg/mL). The 
polymer derivatives showed tuberculostatic 
activity and the MICs observed are displayed in 
Table 1. 
 
Stability studies  
Stability test of micelles consisted of visual 
control and analytical measurement of drugs 
contents. 
No sedimentation or phase separation was 
observed during the 3-month stability test. The 
spectrophotometric spectra remained 
unchanged after 3 months, showing that no 
chemical degradation  took place. Lyophilized of 
polymeric micelles did not change in 3 months 
showing the high storage stability of this 
formulation. In the aqueous form of polymeric 
micelles, a 12,33%, 14,21% and 16,32% 





Our approach to tuberculostatic delivery through 
polymeric micelles was to design with care the 
chemical composition and architecture of the 
amphiphilic polymers forming the polymeric 
micelle. By the condensation of 
hydroxymethylpyrazinamide, isoniazid and 
rifampin with free carboxyl groups on the 
copolymer poly(ethyleneglycol)-poly(aspartic 
acid), micelle-forming carrier-drug conjugates 
were obtained. The presence of a covalently 
bonded drug molecule may have a steric effect 
on the core packing that could potentially impact 
the release rate of the drug. In addition, 
covalently linked tuberculostatic agents will be 
released when the ester or amide linkages are 
cleaved in the same manner as the polymer 
backbone. This has been shown in other 
systems to extend release over physically 
entrapped drug.  
When the concentration reaches the CMC, the 
physicochemical properties of solutions of 
amphiphilic molecules go through an abrupt 
change. Therefore, the CMC can be found by 
observing the variation, with concentration, of 
properties such as hydrophobic dye solubility, 
surface tension or conductivity. While the CMC 
is not really a single concentration but a band, its 
range is often found to be sufficiently narrow for 
the band to be treated as a point
20,21
. The CMC 
of polymeric micelles can be estimated by 
fluorescence spectroscopy. The CMCs of PEG-
PASP-PZA, PEG-PASP-INH  and PEG-PASP-
INH-RMP were obtained from curves 
representing the process of solubilization of 
Sudan III in their solutions, at various polymer 
concentrations in the range 5 x 10
-8
 to 5 x 10
-1
 
mg/L. The onset of micelle formation can be 
seen clearly, in plots of light absorbance against 
concentration, as a sharp change in the slope of 
the curve, which occurs where the dye, insoluble 
in water but soluble in the hydrophobic 
compartment in the micelle, starts to be taken up 
by the solution. Thus, below the CMC, the curve 
is virtually a plateau, while above this 
concentration it rises steadily with the number of 
micelles formed. In this way, the CMC was found 
to be 5.0x10
-4
 mg/L for PEG-PASP-PZA and 
PEG-PASP-INH and 5.0x10
-5
 mg/L for PEG-
PASP-INH-RMP. 
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The size of micelles is controlled by the length of 
the core-forming segment and the length of the 
corona-forming chain
18,19,21
, but it depends also 
on the method of micellization selected for the 
preparation of micelles. For micelles produced 
using the dialysis method, it varies depending on 
the organic solvent employed. The choice of 
organic solvent also affects the yield of 
micellization. Note that, above all, it is important 
to select conditions that minimize the formation 
of large polymer aggregates (diameter > 300 





The mean micelle diameters of PEG-PASP-PZA, 
PEG-PASP-INH and PEG-PASP-INH-RMP were 
shown, by the technique of dynamic light 
scattering, to be 78.2, 84.2 and 98.9 nm, 
respectively, and the distribution of diameters 
has a single peak, as can be seen in the curves. 
In all cases, the size distribution was unimodal, 
indicative of the absence of free polymer chains 
and of large aggregates. In order to obtain such 
small micelles, with a monomodal size 
distribution, several precautions were taken 
during the preparation of the derivatives: 
rigorous control of temperature and constant 
stirring during the synthesis of PEG-PBLA, 
followed by sonication of the product mixture for 
half an hour; elution of the derivative solutions 
through a Sephadex® column, with distilled 
water, and ultrafiltration through a YM3 43 mm 
10 PK membrane. It has been shown that the 
uptake of particles within the intestine and the 
extent of drug absorption increase with 
decreasing particle size and increasing specific 
surface area
21
. Thus, the small size exhibited by 
all the polymeric micelles studied shows a 
favorable trend toward oral drug delivery. Since 
polymeric micelles are a relatively new carrier, it 
is important that several system characteristics 
be elucidated
22,23,24
, such as stability, 
mechanism release and activity.  
 
Micellar structure is strongly affected by 
temperature. The temperature at which micelles 
are formed is known as critical micellization 
temperature (CMT). For most copolymers this 
value is 25-40 
o
C. If micelles were kept in 
refrigerator, temperature would fall lower than 
CMT, thus micelles would lose their intact 
structure and drug would precipitate. For this 
reason, stability test was performed at 25 
o
C. 





 since the drugs 
incorporated there - isoniazid, pyrazinamide and 
rifampin - exhibit a rather strict structure-function 
relationship that would demand release of the 
drug moiety for the biological activity to be 
effective, i.e. the micelles act as prodrugs. 
 
There is an increasing appreciation for the role 
of nontuberculous mycobacteria as pathogens 
causing pulmonary disease, disseminated 




Mycobacterium kansasii usually causes chronic 
lung infection resembling pulmonary 
tuberculosis. Cases of soft tissue or bone and 
joint infections have also reported. The 
recommended treatment regimen for these 
infections is a combination of rifampin, isoniazid, 
and ethambutol
25,26,27
. M. xenopi, M. simae, and 
M. malmoense are infrequent human pathogens 
but also appear to be increasing in prevalence
27
. 
Particularly M. malmoense next to M. 
tuberculosis and M. avium complex, it is the 
most common cause of mycobacterial infection 
in certain geographic locations
26,29
. These 
nontuberculous mycobacteria species cause 
lymphadenitis or chronic pulmonary infection. 
The in vitro susceptibilities of these organisms 
and the results of chemotherapy have been 
variable. Conventional therapy of M. malmoense 
infections with antituberculosis drugs is often of 
limited value, and there is thus a need for 
improved drug regimens
27
. Like most other 
atypical mycobacteria, it has a high degree of 
resistance to antibacterial drugs, including 
specific antituberculosis drugs such as p-
aminosalicylic acid, ethambutol, isoniazid and 
pyrazinamide. 
 
As mentioned in the experimental section, PZA, 
INH, RMP and polymer derivative were tested 
against seven strains of Mycobacterium. When 
the MICs of the polymer derivatives were 
recalculated in terms of the weights of the active 
drug moieties conjugated to the PEG-PASP 
carrier, instead of the total weight of polymer, the 
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increase in activity (decrease in MIC) of the 
polymer-bound drugs, relative to the free, was 
about 15-fold for PEG-PASP-INH and PEG-
PASP-INH-RMP and about 13-fold for PEG-
PASP-PZA. In this sense, the micelle-forming 
derivatives all showed stronger anti-
mycobacterial activity than the original drugs. Of 
particular note, good activity was obtained 
against strains considered drug-resistant and 
commonly recovered from HIV-infected patients. 
This potentiation of the drug activity when 
conjugated to the polymer is clearly promising 
with regard to possible reductions in the dose 




Polymeric micelles of tuberculostatics were 
obtained, characterized and tested against 
Mycobacterium strains, showing excellent 
characteristics, as promising drug carrier 
systems. In the organism expected that the 
drugs are released following internalization of 
micelle, by cleavage, i.e. its act as prodrugs 
These micelles are able to increase a 
hydrophobic drug’s solubility, to reduce drug 
toxicity, improve drug bioavailability, target drug 
delivery to a specific site, and sustain release 
systemically, prolonging the drug action.  
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